Published in Lancet on October 22, 1977
Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J (Clin Res Ed) (1984) 1.83
Monitoring effects of oral anticoagulants during treatment with heparin. Br Med J (Clin Res Ed) (1984) 1.18
A model which predicts maintenance warfarin dosage requirements from the response to a single dose. Br J Clin Pharmacol (1985) 0.81
The Smith Kline & French lecture 1987. Clinical pharmacology and the art of bespoke prescribing. Br J Clin Pharmacol (1988) 0.77
Warfarin dosage requirements: prospective clinical trial of a method for prediction from the response to a single dose. Br J Clin Pharmacol (1988) 0.75
Control of warfarin therapy. Postgrad Med J (1990) 0.75
Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 6.89
Review of company postmarketing surveillance studies. BMJ (1992) 6.21
Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol (1995) 4.72
Monitoring adverse reactions to drugs. Br Med J (1977) 4.41
A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. Br J Psychiatry (1990) 3.74
Infant crying and maternal responsiveness. Child Dev (1972) 3.68
Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ (2007) 3.26
Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed) (1985) 2.97
Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol (2007) 2.97
Studies of vitamin D deficiency in man. Q J Med (1975) 2.94
Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol (1999) 2.78
Comprehensive clinical drug information service: first year's experience. Br Med J (1977) 2.77
The failings of NICE. Reply from chairman of NICE. BMJ (2001) 2.55
Activity of aryl hydrocarbon hydroxylase in psoriatic skin. Lancet (1979) 2.54
Clinical pharmacology in the National Health Service. J R Soc Med (1978) 2.54
Attitudes to adverse drug reaction reporting in the Northern Region. Br J Clin Pharmacol (1992) 2.51
Clinical pharmacology in a district general hospital. Lancet (1976) 2.47
Prescribing at the interface between hospitals and general practitioners. BMJ (1992) 2.47
The role of the pharmaceutical industry in postgraduate medical education. Br J Clin Pharmacol (1977) 2.45
Clinical pharmacology clinics in general practice. Br Med J (1977) 2.28
Mechanisms of ampicillin resistance in Haemophilus influenzae from respiratory tract. Lancet (1980) 2.16
Changing patterns of self-poisoning in a UK health district. QJM (1996) 2.13
Doctors and the drug makers. Lancet (1984) 2.09
Use of split-skin grafting in the treatment of chronic leg ulcers. Ann R Coll Surg Engl (1995) 2.06
Extending the role of the community pharmacist. BMJ (1991) 2.05
Reporting of adverse drug reactions by hospital pharmacists: pilot scheme. BMJ (1997) 1.96
Factors affecting warfarin requirements. A prospective population study. Eur J Clin Pharmacol (1979) 1.95
Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technology. Br J Cancer (1993) 1.93
Attachment, exploration, and separation: illustrated by the behavior of one-year-olds in a strange situation. Child Dev (1970) 1.89
Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer (1997) 1.87
Generalised tissue abnormality of aryl hydrocarbon hydroxylase in psoriasis. Br Med J (1980) 1.87
Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol (2000) 1.84
Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J (Clin Res Ed) (1984) 1.83
Clinical pharmacokinetics of propranolol. Clin Pharmacokinet (1979) 1.81
Review of yellow cards--1986 and 1987. Br Med J (Clin Res Ed) (1988) 1.81
The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology (1989) 1.80
[Reasons to report or not report side effects of drugs to the national monitoring system in the Netherlands]. Ned Tijdschr Geneeskd (1995) 1.79
Letter: How do doctors learn about drugs? Lancet (1975) 1.78
Anticoagulants in venous thromboembolism. BMJ (1988) 1.77
Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. Eur J Clin Pharmacol (1977) 1.76
Lidocaine plasma protein binding. Clin Pharmacol Ther (1980) 1.74
Psoriasis and cancer. Br Med J (1979) 1.71
Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed) (1987) 1.69
Adenosine stimulates respiration in man. Br J Clin Pharmacol (1985) 1.67
New active substances authorized in the United Kingdom between 1972 and 1994. Br J Clin Pharmacol (1998) 1.67
Drug information centres: a clinical pharmacologist's view. Proc R Soc Med (1977) 1.66
Pharmacokinetics and clinical toxicity of quinine overdosage: lack of efficacy of techniques intended to enhance elimination. Q J Med (1985) 1.65
Safety of late acetylcysteine treatment in paracetamol poisoning. Hum Exp Toxicol (1990) 1.65
Random and systematic medication errors in routine clinical practice: a multicentre study of infusions, using acetylcysteine as an example. Br J Clin Pharmacol (2001) 1.63
Methylation and colorectal cancer. J Pathol (2001) 1.61
Postmarketing surveillance of adverse reactions to drugs. Br Med J (Clin Res Ed) (1984) 1.57
Phosphate enemas in childhood: cause for concern. BMJ (1991) 1.55
Carbapenem-hydrolysing metallo-beta-lactamases from Klebsiella pneumoniae and Escherichia coli isolated in Australia. Pathology (2004) 1.52
A proposal to standardize terminology for weak D antigen. Transfusion (1992) 1.52
Expression of the catalytic subunit of cAMP-dependent protein kinase in Escherichia coli: multiple isozymes reflect different phosphorylation states. Protein Eng (1993) 1.52
The plasma protein binding of basic drugs. Br J Clin Pharmacol (1986) 1.49
Medical experience in nuclear submarines. J R Nav Med Serv (1971) 1.47
Intravenous salbutamol and cardiogenic shock. Lancet (1972) 1.46
Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. Br Med J (Clin Res Ed) (1987) 1.46
Accidental hypothermia treated by extracorporeal blood warming. Lancet (1967) 1.46
Low prevalence of hepatitis B in mental handicap hospital. Lancet (1989) 1.45
Hospital prescribing and usage of hypnotics and anxiolytics. Br J Clin Pharmacol (1991) 1.44
Atropine as possible contaminant of comfrey tea. Lancet (1989) 1.43
Reducing arthroplasty costs via vendor contracts. Can J Surg (1999) 1.43
Geographical differences in adverse drug reaction reporting rates in the Northern Region. Br J Clin Pharmacol (1991) 1.43
The CDS disc method of antibiotic sensitivity testing (calibrated dichotomous sensitivity test). Pathology (1975) 1.43
Rubella in mothers. Lancet (1996) 1.43
Community exposures to chemical incidents: development and evaluation of the first environmental public health surveillance system in europe. J Epidemiol Community Health (2000) 1.39
Spontaneous periodic hypothermia: diencephalic epilepsy. Br Med J (1973) 1.39
Extrapyramidal reactions to prochlorperazine and haloperidol in the United Kingdom. Q J Med (1986) 1.39
Women's satisfaction with medical abortion with RU486. Med J Aust (1997) 1.39
The effect of intravenous aminophylline on essential tremor. Br J Clin Pharmacol (1997) 1.38
Lipid emulsification after implant rupture. Br J Plast Surg (1999) 1.38
Resistance of Pseudomonas aeruginosa to carbenicillin. Lancet (1969) 1.37
Which drug for the adult epileptic patient: phenytoin or valproate? Br Med J (Clin Res Ed) (1985) 1.36
Pharmacokinetics and pharmacodynamics of warfarin at steady state. Br J Clin Pharmacol (1979) 1.36
Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction. Ann Intern Med (1980) 1.35
Clinical pharmacology. Adverse reactions to drugs. Br Med J (Clin Res Ed) (1981) 1.35
Lignocaine disposition in blood in epilepsy. Br J Clin Pharmacol (1981) 1.35
Complications of radial forearm flap donor sites. Br J Plast Surg (1986) 1.33
Absence of the Birt-Hogg-Dubé gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility. Oncogene (2010) 1.33
A method for obtaining saliva samples from infants and young children. Br J Clin Pharmacol (1978) 1.32
Sex-related differences in the plasma protein binding of lignocaine and diazepam. Br J Clin Pharmacol (1981) 1.32
Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ (1999) 1.31
Clarithromycin appears to be linked with Clostridium difficile-associated diarrhoea in the elderly. J Antimicrob Chemother (2000) 1.29
Transient bradycardia and subsequent sinus tachycardia produced by intravenous adenosine in healthy adult subjects. Br J Clin Pharmacol (1986) 1.29
High-performance liquid chromatographic analysis of isoniazid and acetylisoniazid in biological fluids. J Chromatogr (1983) 1.27
Free and total plasma theophylline concentrations in chronic airflow obstruction. Thorax (1984) 1.26
Identification of phosphorylation sites in the recombinant catalytic subunit of cAMP-dependent protein kinase. J Biol Chem (1993) 1.26
Prazosin, pharmacokinetics and concentration effect. Eur J Clin Pharmacol (1979) 1.26
Accidental poisoning in children: can we admit fewer children with safety? Arch Dis Child (1991) 1.25
The effects of salicylate on temperature regulation in the rabbit. J Physiol (1970) 1.24